ACS Chemical Neuroscience Molecule Spotlight on Valdoxen

作者：Hopkins Corey R^*

来源：ACS Chemical Neuroscience, 2010, 1(12): 772-773.

DOI：10.1021/cn100062j

• Valdoxen
• major depressive disorders
• MDD
• norepinephrine-dopamine
• disinhibitor
• NNDI

A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2c) receptor.

• 出版日期2010-12